Linabite D 10mg/5mg Tablet is a fixed-dose combination medication containing Dapagliflozin 10mg and Linagliptin 5mg, indicated for the management of type 2 diabetes mellitus. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that promotes renal glucose excretion, thereby reducing plasma glucose levels independently of insulin secretion. Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances incretin hormone levels, leading to increased insulin release and decreased glucagon secretion in a glucose-dependent manner. The combination of these agents offers complementary mechanisms of action, improving glycemic control by targeting both renal glucose reabsorption and pancreatic hormone regulation. Linabite D is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly in patients inadequately controlled on monotherapy. It may be used alone or in combination with other antidiabetic agents, including insulin. The medication should be administered once daily, with or without food. Caution is advised in patients with renal impairment, and monitoring for potential adverse effects such as urinary tract infections, hypoglycemia, and volume depletion is recommended. Linabite D should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize risks.